Recombinant protein targeting PD-1 and TGFß
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Oct 31, 2023
Grant Date -
N/A
app pub date -
Oct 20, 2020
filing date -
Oct 21, 2019
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
A recombinant fusion protein comprising 1) TGFβR2, or a fragment thereof, capable of binding to TGFβ, and 2) an antibody, or an antigen-binding fragment thereof, that binds to PD-1. Also disclosed are a polynucleotide encoding the recombinant fusion protein, an expression vector containing the polynucleotide, a method for producing the recombinant protein and a method for treating a disease caused by over expression of TGFβ and/or PD-1 using the recombinant protein.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully